9 METERS BIOPHARMA, INC. Annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD from 2015 to 2022
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
9 Meters Biopharma, Inc. quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from 2015 to 2022.
- 9 Meters Biopharma, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending March 31, 2023 was -$13.9M, a 22.2% decline year-over-year.
- 9 Meters Biopharma, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending March 31, 2023 was -$46.3M, a 8.39% decline year-over-year.
- 9 Meters Biopharma, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was -$43.8M, a 19% decline from 2021.
- 9 Meters Biopharma, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2021 was -$36.8M, a 40.2% increase from 2020.
- 9 Meters Biopharma, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2020 was -$61.5M, a 127% decline from 2019.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Growth (%)